{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:43:13Z","timestamp":1790689393467,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.lanepe.2024.100887","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:38:03Z","timestamp":1711096683000},"page":"100887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-1304","authenticated-orcid":false,"given":"Borislava","family":"Mihaylova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6523-5754","authenticated-orcid":false,"given":"Runguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-0944","authenticated-orcid":false,"given":"Junwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Schlackow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Reith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Parnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lanepe.2024.100887_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9753","key":"10.1016\/j.lanepe.2024.100887_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.lanepe.2024.100887_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.lanepe.2024.100887_bib4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.lanepe.2024.100887_bib5","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lanepe.2024.100887_bib6","article-title":"Cardiovascular disease: risk assessment and reduction, including lipid modification","year":"2023","journal-title":"Clin Guideline"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100887_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/pds.5023","article-title":"The impact of statin discontinuation and restarting rates on the optimal time to initiate statins and on the number of cardiovascular events prevented","volume":"29","author":"Pate","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100887_bib8","first-page":"388","article-title":"Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017","volume":"109","author":"Thalmann","year":"2023","journal-title":"Heart"},{"issue":"8A","key":"10.1016\/j.lanepe.2024.100887_bib9","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"10355","key":"10.1016\/j.lanepe.2024.100887_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"9716","key":"10.1016\/j.lanepe.2024.100887_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.lanepe.2024.100887_bib12","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.lanepe.2024.100887_bib13","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100887_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ije\/dyz099","article-title":"National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries","volume":"49","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100887_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era","volume":"124","author":"Lazar","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.lanepe.2024.100887_bib16","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/CIRCULATIONAHA.121.057631","article-title":"Beyond 10-year risk: a cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease","volume":"145","author":"Kohli-Lynch","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100887_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamacardio.2019.2851","article-title":"Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk","volume":"4","author":"Kohli-Lynch","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"10170","key":"10.1016\/j.lanepe.2024.100887_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"issue":"7404","key":"10.1016\/j.lanepe.2024.100887_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2024.100887_bib20","series-title":"Drug tariff December 2021","author":"NHS Prescription Services","year":"2021"},{"key":"10.1016\/j.lanepe.2024.100887_bib21","series-title":"Unit costs of health and social care 2020","author":"Curtis","year":"2020"},{"key":"10.1016\/j.lanepe.2024.100887_bib22","series-title":"National schedule of NHS costs 2019\/20","author":"NHS England","year":"2021"},{"issue":"740","key":"10.1016\/j.lanepe.2024.100887_bib23","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.3399\/BJGP.2023.0198","article-title":"Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model","volume":"74","author":"Wu","year":"2023","journal-title":"Br J Gen Pract"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100887_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40273-022-01219-6","article-title":"Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK","volume":"41","author":"Zhou","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.lanepe.2024.100887_bib25","series-title":"NICE health technology evaluations: the manual","year":"2022"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100887_bib26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing generic drug markets in Europe and the United States: prices, volumes, and spending","volume":"95","author":"Wouters","year":"2017","journal-title":"Milbank Q"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100887_bib27","article-title":"Cost-effectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary Artery disease patients","volume":"6","author":"Stam-Slob","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.lanepe.2024.100887_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100887_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7326\/0003-4819-150-4-200902170-00005","article-title":"Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering","volume":"150","author":"Pletcher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100887_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100887_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.lanepe.2024.100887_bib32","doi-asserted-by":"crossref","first-page":"c2442","DOI":"10.1136\/bmj.c2442","article-title":"An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study","volume":"340","author":"Collins","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100887_bib33","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S2214-109X(21)00551-9","article-title":"Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data","volume":"10","author":"Marcus","year":"2022","journal-title":"Lancet Glob Health"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622400053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622400053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T05:49:08Z","timestamp":1714974548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266677622400053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"alternative-id":["S266677622400053X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100887","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100887"}}